JP2012502071A5 - - Google Patents

Download PDF

Info

Publication number
JP2012502071A5
JP2012502071A5 JP2011526411A JP2011526411A JP2012502071A5 JP 2012502071 A5 JP2012502071 A5 JP 2012502071A5 JP 2011526411 A JP2011526411 A JP 2011526411A JP 2011526411 A JP2011526411 A JP 2011526411A JP 2012502071 A5 JP2012502071 A5 JP 2012502071A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
formulated
composition according
peptide
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011526411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502071A (ja
Filing date
Publication date
Priority claimed from EP08016142A external-priority patent/EP2163259B1/en
Application filed filed Critical
Publication of JP2012502071A publication Critical patent/JP2012502071A/ja
Publication of JP2012502071A5 publication Critical patent/JP2012502071A5/ja
Pending legal-status Critical Current

Links

JP2011526411A 2008-09-12 2009-09-11 急性肺損傷におけるang−(1−7)レセプターアゴニストの使用 Pending JP2012502071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08016142.5 2008-09-12
EP08016142A EP2163259B1 (en) 2008-09-12 2008-09-12 Use of an Ang-(1-7) receptor agonist in acute lung injury
PCT/EP2009/006619 WO2010028845A2 (en) 2008-09-12 2009-09-11 Use of an ang-(1-7) receptor agonist in acute lung injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013257932A Division JP5881122B2 (ja) 2008-09-12 2013-12-13 急性肺損傷におけるang−(1−7)レセプターアゴニストの使用

Publications (2)

Publication Number Publication Date
JP2012502071A JP2012502071A (ja) 2012-01-26
JP2012502071A5 true JP2012502071A5 (cg-RX-API-DMAC7.html) 2013-05-16

Family

ID=40430691

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011526411A Pending JP2012502071A (ja) 2008-09-12 2009-09-11 急性肺損傷におけるang−(1−7)レセプターアゴニストの使用
JP2013257932A Expired - Fee Related JP5881122B2 (ja) 2008-09-12 2013-12-13 急性肺損傷におけるang−(1−7)レセプターアゴニストの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013257932A Expired - Fee Related JP5881122B2 (ja) 2008-09-12 2013-12-13 急性肺損傷におけるang−(1−7)レセプターアゴニストの使用

Country Status (9)

Country Link
US (4) US20110281805A1 (cg-RX-API-DMAC7.html)
EP (2) EP2163259B1 (cg-RX-API-DMAC7.html)
JP (2) JP2012502071A (cg-RX-API-DMAC7.html)
KR (1) KR20110074978A (cg-RX-API-DMAC7.html)
CN (2) CN103263661A (cg-RX-API-DMAC7.html)
BR (2) BR122013002187A2 (cg-RX-API-DMAC7.html)
CA (1) CA2736922C (cg-RX-API-DMAC7.html)
ES (1) ES2393455T3 (cg-RX-API-DMAC7.html)
WO (1) WO2010028845A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2393455T3 (es) * 2008-09-12 2012-12-21 Charité-Universitátsmedizin Berlin (Charité) Uso de un agonista del receptor Ang-(1-7) en lesiones pulmonares agudas
JP2015504870A (ja) * 2011-12-16 2015-02-16 タリックス ファーマシューティカルズ リミテッド 線維症を処置するためのアンジオテンシン
CN102532265A (zh) * 2011-12-29 2012-07-04 中国人民解放军第四军医大学 一种短肽、其异构体及其应用
US20130210726A1 (en) * 2012-02-10 2013-08-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
CA2884792A1 (en) * 2012-09-17 2014-03-20 Tarix Pharmaceuticals Ltd. Oral formulations of angiotensin
US8633158B1 (en) * 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
CN105636645A (zh) * 2013-04-19 2016-06-01 爱荷华大学研究基金会 在肌萎缩症中的血管紧张素
JP2016520592A (ja) * 2013-05-24 2016-07-14 タリックス ファーマシューティカルズ リミテッド マルファン症候群および関連障害の処置におけるアンジオテンシンペプチド
WO2015054005A1 (en) * 2013-10-11 2015-04-16 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of bdnf-related conditions
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
RU2016152088A (ru) * 2014-07-17 2018-08-21 Юниверсити Оф Саузерн Калифорния Способы, соединения и композиции для лечения заболеваний опорно-двигательного аппарата
CN106535920B (zh) 2014-07-21 2020-10-30 代表亚利桑那大学的亚利桑那校董会 Ang-(1-7)衍生物寡肽及其使用和生产方法
US10183055B2 (en) * 2014-07-21 2019-01-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications
JP7010698B2 (ja) * 2015-04-08 2022-01-26 コーニンクレッカ フィリップス エヌ ヴェ 急性呼吸促迫症候群(ards)のリスクスコアによって導かれる換気治療推薦のためのツール
WO2018129511A2 (en) * 2017-01-09 2018-07-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Ang-(1-7) and derivative oligopeptides for the treatment of traumatic brain injury and other cognitive impairments
US20200188473A1 (en) * 2017-05-02 2020-06-18 Beth Israel Deaconess Medical Center, Inc. Combination therapy for cancer
CN112316107B (zh) * 2019-07-17 2023-01-06 首都医科大学附属北京妇产医院 血管紧张素(1-7)在胰腺疾病中的应用
WO2021183863A1 (en) * 2020-03-13 2021-09-16 Constant Therapeutics Llc Methods and compositions for treatment of coronavirus infection
WO2022094025A1 (en) * 2020-10-30 2022-05-05 Gere Dizerega Angiotensin-1-7 for the treatment of covid-19
US12343331B2 (en) 2021-01-28 2025-07-01 Capacity Bio, Inc. Methods and agents that stimulate mitochondrial turnover for treating disease
EP4085921A1 (en) 2021-05-04 2022-11-09 CU-Pharmaceuticals UG Angiotensin-(1-7) in the treatment of sars-cov related diseases
CN117147877A (zh) * 2023-08-30 2023-12-01 重庆医科大学附属儿童医院 Ang1-7作为生物标志物在预测、诊断儿童脓毒症中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110895A (en) * 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
YU78601A (sh) 1999-05-05 2005-07-19 Aventis Pharma Deutschland Gmbh. 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže
AU2003217783A1 (en) * 2002-02-27 2003-09-09 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
US20050119180A1 (en) * 2002-03-28 2005-06-02 Roks Antonius J.M. Use of angiotensin 1-7 for enhancing cardiac function
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
BRPI0503122A (pt) 2005-05-30 2007-05-02 Univ Minas Gerais composições farmacêuticas do peptìdeo angiotensina-(1-7) [ang-(1-7)] e seus análogos, agonistas e antagonistas usando as ciclodextrinas, seus derivados, e o polìmeros biodegradáveis e/ou dos produtos derivados para uso no controle das funções do sistema reprodutivo
BRPI0502497A (pt) 2005-06-28 2007-02-06 Univ Minas Gerais uso de agonistas e antagonistas do receptor acoplado a proteìna g, mas, como moduladores de atividade apoptótica para o estudo, a prevenção e o tratamento de doenças
BRPI0602366B1 (pt) 2006-04-26 2017-12-12 Universidade Federal De Minas Gerais Use of agonists of the receptor coupled to protein g, but, in the treatment of metabolic syndrome, its components and their complications
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
ES2393455T3 (es) * 2008-09-12 2012-12-21 Charité-Universitátsmedizin Berlin (Charité) Uso de un agonista del receptor Ang-(1-7) en lesiones pulmonares agudas

Similar Documents

Publication Publication Date Title
MX2010001839A (es) Metodo y aparato para comunicacion y metodo y aparato para controlar comunicacion.
WO2011080102A3 (en) Glp-1 analogues and derivatives
AU2007295179A1 (en) Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
JP2005524658A5 (cg-RX-API-DMAC7.html)
JP2009102342A5 (cg-RX-API-DMAC7.html)
JP2010504343A5 (cg-RX-API-DMAC7.html)
WO2009006095A3 (en) Dual portion lozenge dosage form
AR075148A1 (es) Formulacion de rasagilina de liberacion retardada. proceso para fabricar citrato de rasagilina
JP2008533007A5 (cg-RX-API-DMAC7.html)
JP2009535352A5 (cg-RX-API-DMAC7.html)
MY155402A (en) Pharmaceutical composition of a potent hcv inhibitor for oral administration
WO2008069917A3 (en) Novel cyclic peptides
JP2013542247A5 (cg-RX-API-DMAC7.html)
NZ597858A (en) Vaccines and compositions against streptococcus pneumoniae
JP2010536889A5 (cg-RX-API-DMAC7.html)
WO2009043926A3 (en) Oral fast disintegrating tablets
CY1127230T1 (el) Φαρμακευτικη συνθεση για απο του στοματος χορηγηση περιλαμβανουσα κρυσταλλικα αλατα του αμιδιου (4s,4as,5ar,12as)-4-διμεθυλαμινο- 3,10,12,12α-τετραϋδροξυ-7-[(μεθοξυ(μεθυλ)αμινο)- μεθυλ]-1,11 -διοξο 1,4,4α,5,5α,6,11,12α-οκταϋδρο- ναφθακενο-2-καρβοξυλικου οξεος
JP2010511663A5 (cg-RX-API-DMAC7.html)
NZ597488A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
JP2023071670A5 (cg-RX-API-DMAC7.html)
NZ600583A (en) Visfatin therapeutic agents for the treatment of acne and other conditions
WO2010082220A3 (en) Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
JP2011528897A5 (cg-RX-API-DMAC7.html)
PH12013500173A1 (en) Oral controlled release pharmaceutical compositions of blonanserin
WO2007095661A8 (en) Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition